Chemotherapy Archives - Medical Conferences

Pre-operative chemoradiation does not improve survival in resectable gastric cancer

Presented By

Prof. Trevor Leong, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, TOPGEAR

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:10

Peri- or post-operative chemotherapy benefits patients with resectable CRCLM

Presented By

Dr Giacomo Bregni, Brussels University Hospital, Belgium

Trial

Phase 3

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:12

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By

Prof. Jens Höppner, University of Bielefeld, Germany

Trial

Phase 3, ESOPEC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:14

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By

Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Trial

Phase 3, GABARNANCE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:06

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

Adding docetaxel to standard-of-care does not improve outcomes in gastric cancer

Presented By

Dr Anant Ramaswamy, Tata Memorial Centre, India

Trial

Phase 3, DOC-GC

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:37

KEYNOTE-590: 5-Year outcomes confirm benefit of pembrolizumab in oesophageal cancer

Presented By

Prof. Manish Shah, Weill Cornell Medicine, NY, USA

Trial

Phase 3, KEYNOTE-590

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:26

New standard-of-care for locally advanced oesophageal squamous cell carcinoma?

Presented By

Prof. Yin Li, National Cancer Center, China

Trial

Phase 3, ESCORT-NEO

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:23

SKYSCRAPER-08: Adding tiragolumab to oesophageal cancer regimen improves outcomes

Presented By

Prof. Chih-Hung Hsu, National Taiwan University Hospital, Taiwan

Trial

Phase 3, SKYSCRAPER-08

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:17

CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab

Presented By

Prof. Ian Chau, Royal Marsden Hospital, UK

Trial

Phase 3, CheckMate 648

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:13

CheckMate 649: Nivolumab plus chemotherapy continues to deliver efficacy benefit in gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, CheckMate 649

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:03

Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL

Presented By

Prof. Martin Schrappe, Hong Kong College of Paediatricians, China

Trial

Phase 3, AIEOP-BFM ALL 2017

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By

Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain

Trial

Phase 3, ANITA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:43

Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC

Presented By

Prof. Herbert Ho Fung Loong, Chinese University of Hong Kong, China

Trial

Phase 3, LIBRETTO-431

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:54

DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma

Presented By

Prof. Martine Chamuleau, Amsterdam UMC, the Netherlands

Trial

Phase 3, HOVON/SAKK

Conference

EHA 2022

Type

News article

1 July 2022 11:32

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April 2022 10:43

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By

Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma

Presented By

Dr Chigusa Morizane, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1213, TOPIC-NEC

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 12:26

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

Presented By

Prof. Karyn Goodman, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:22

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1109, NExT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:13

No benefit of additional oxaliplatin in elderly patients with mCRC

Presented By

Dr Tetsuya Hamaguchi, National Cancer Center, Japan

Trial

Phase 3, JCOG1018, RESPECT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:19

Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled

Presented By

Dr Claire Gallois, Université de Paris, France

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:17

Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy

Presented By

Dr Kevin Kalinsky, Emory University Winship Cancer Institute, GA, USA

Trial

Phase 3, RxPONDER

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:19

Novel conjugate meets primary endpoint

Presented By

Dr Cristina Saura, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, TULIP

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:50

BrighTNess data may change guidelines

Presented By

Prof. Sibylle Loibl, German Breast Group, Germany

Trial

Phase 3, BrighTNess

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:49

Double-positive results for triple-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, University of California, San Francisco, USA

Trial

Phase 3, KEYNOTE-355

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:48

Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy

Presented By

Prof. Valentina Guarneri, University of Padua, Italy

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:48

No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better

Presented By

Prof. Miguel Martín Jiménez, Complutense University of Madrid, Spain

Trial

Phase 3, PEARL

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:45

Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC

Presented By

Dr Pei-Rong Ding, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, CONVERT

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:43

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate649

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

HIPEC in gastric cancer with peritoneal metastases

Presented By

Prof. Beate Rau, Charité University Hospital Berlin, Germany

Trial

Phase 3, GASTRIPEC I

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By

Dr Alexander Stein, University Cancer Center Hamburg, Germany

Trial

Phase 2, INTEGA

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:39

Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM

Presented By

Prof. Solange Peters, Lausanne University Hospital, Switzerland

Trial

Phase 3, CheckMate743

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:36

Three-year OS follow-up from CASPIAN trial

Presented By

Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:32

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:27

Better survival with neoadjuvant dose-dense MVAC regimen in MIBC

Presented By

Dr Christian Pfister, Rouen University Hospital, France

Trial

Phase 3, VESPER

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:25

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By

Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy

Trial

Phase 3, KEYNOTE-826

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:23

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By

Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, NRG-GY004

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:20

Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC

Presented By

Dr Jonathan Spicer, McGill University, Canada

Trial

Phase 3, CheckMate 816

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:59

Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Presented By

Prof. Thierry André, Sorbonne University, France

Trial

Phase 3, KEYNOTE 177

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:32

Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer

Presented By

Prof. Linda Mileshkin, Peter MacCallum Cancer Center, Australia

Trial

Phase 3, OUTBACK

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:24

Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC

Presented By

Prof. Dominik Modest, Charité Universitätsmedizin Berlin, Germany

Trial

Phase 3, PANAMA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:34

Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

Presented By

Prof. Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

Phase 3, CheckMate 9LA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:00

Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine

Presented By

Prof. Ingrid Mayer, Vanderbilt University School of Medicine, TN, USA

Trial

Phase 3, ECOG-ACRIN EA1131

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:50

Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer

Presented By

Dr Ian Chau, Royal Marsden Hospital, UK

Trial

Phase 3, CheckMate 648

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:12

Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Presented By

Prof. Markus Moehler, Mainz University Clinic, Germany

Trial

Phase 3, CheckMate 649

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 19:15

Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Presented By

Prof. John Reynolds, Trinity St James Cancer Institute, Ireland

Trial

Phase 3, Neo-AEGIS

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 13:18

Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab

Presented By

Dr. Khalid Jazieh, Cleveland Clinic, Ohio, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:24

Chemoimmunotherapy is effective in a subset of small cell lung cancer patients

Presented By

Prof. Taofeek Owonikoko, Emory University School of Medicine

Trial

KEYNOTE-604, ECOG-ACRIN EA5161

Journal

Physician’s Weekly

Conference

ASCO20 Virtual Meeting

15 April 2021 16:03

How to avoid chemotherapy overtreatment in breast cancer

Presented By

Dr Nadia Harbeck , University of Munich in Germany

Trial

ADAPT

Journal

Physician’s Weekly

Conference

SABCS 2020

13 April 2021 17:22

ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman

Presented By

Prof. Jonathan Goldman, Prof. Luis Paz-Ares

Trial

Phase 3, CASPIAN

Journal

Physician Weekly

Conference

ASCO Annual Meeting 2020

13 April 2021 16:27

First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC

Presented By

Dr Kai-Keen Shiu, University College London Hospitals NHS Foundation Trust, UK

Trial

Phase 3, KEYNOTE-177

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:52

Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients

Presented By

Dr Eric Francois, Centre Antoine-Lacassagne, France

Trial

PRODIGE 42-GERICO 12 NACRE

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:50

Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels

Presented By

Prof. Zev Wainberg, UCLA, USA

Trial

Phase 2, FIGHT

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:50

Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results

Presented By

Dr Osama Rahma, Dana-Farber Cancer Institute, USA

Trial

Phase 2

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:46

Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer

Presented By

Prof. Kazuo Koyanagi, National Cancer Center, Japan

Trial

Phase 3, JCOG 1109

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:42

Adjuvant nivolumab: good quality-of-life

Presented By

Prof. Eric Van Cutsem, University of Leuven, Belgium

Trial

Phase 3, CheckMate 577

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:40

Preliminary surgery salvage data after watch & wait policy from OPERA trial

Trial

Phase 3, OPERA

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:40

Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers

Presented By

Prof. Thomas Seufferlein, University of Ulm, Germany

Trial

Phase 1/2, PERMAD

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:37

Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy

Presented By

Prof. Eric Van Cutsem, KU Leuven, Belgium

Trial

Phase 2, TASCO1

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:35

Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC

Presented By

Dr Valérie Boige, Institut Gustave Roussy, France

Trial

Phase 2, PRODIGE 28-time UNICANCER

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:33

Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy

Presented By

Dr Jeffrey Chi, Northwell Health Cancer Institute, NY, USA

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:31

Borderline resectable pancreatic cancer: phase 2 results

Presented By

Prof. Matthew H. Katz, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2, Alliance A021501

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:12

Metastatic pancreatic adenocarcinoma: second-line naI-IRI plus 5-FU/LV

Presented By

Prof. Kyunghye Bang, Asan Medical Center, Korea

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:59

Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS

Presented By

Dr Matthew Parsons, University of Utah, USA

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:58

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By

Prof. Peter Schmid, Queen Mary University of London, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:12

KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer

Presented By

Dr Josep Tabernero, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, KEYNOTE-062

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 22:56

Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer

Presented By

Dr Kim N. Chi, BC Cancer Agency, Canada

Trial

Phase 3, TITAN

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 22:28

Overcoming the challenges of immunotherapy in non–small cell lung cancer

Presented By

Dr Sarah B. Goldberg, Dr Melissa Lynne Johnson, Dr Alexander Chi

Trial

PACIFIC, KEYNOTE-024, KEYNOTE-189

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 22:04

Neoadjuvant chemotherapy as a potential treatment option in colon cancer

Presented By

Dr Matthew T. Seymour, National Institute for Health Research Clinical Research Network, England

Trial

FOxTROT

Type

Peer-reviewed article

15 July 2019 21:58

Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases

Presented By

Dr Åsmund Avdem Fretland, Oslo University Hospital, Norway

Trial

OSLO-COMET

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 20:01

ImPassion130 brings breast cancer into the immunotherapy era

Trial

Phase 3, ImPassion130

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 11:27

I-O monotherapy

Presented By

Prof. Martin Reck, Airway Research Center North, Grosshansdorf, Germany

Trial

CheckMate 026, Keynote-024, Checkmate 227, MYSTIC, B-F1RST

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 23:13

Combo I-O plus chemotherapy

Presented By

Dr Luis Paz-Ares, Complutense University of Madrid, Spain

Trial

Keynote-189, Impower-132

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 22:15

Post-study immunotherapy in MYSTIC

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Munich-Gauting, Germany

Trial

Phase 3, MYSTIC

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 13:26

Treatment options in early NSCLC

Presented By

Dr Walter Weder, Dr Raffaele Califano

Trial

CALGB 9633

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 13:04

Neoadjuvant therapy and residual disease

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 17:25

Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA

Trial

KATHERINE, CREATE-X

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 16:29

Adjuvant therapy in triple-negative breast cancer

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 12:36

Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer

Presented By

Dr Ariadna Gasol Cudos, Hospital Universitari Arnau de Vilanova de Lleida, Spain

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 09:55

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Trial

Phase 3, CheckMate 227

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 23:44

Combination therapies: Where are we in 2018?

Presented By

Prof. Martin Reck, German Center for Lung Research, Germany

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:05

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer

Presented By

Prof. Balazs Halmos, Albert Einstein College of Medicine and Montefiore Medical Center, USA

Trial

Phase 3, KEYNOTE-407

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 21:18